Wells Fargo Sticks to Their Buy Rating for Editas Medicine (EDIT)
Leerink Partners Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8
Editas Medicine (EDIT) Receives a Hold From RBC Capital
Jones Trading Initiates Coverage On Editas Medicine With Buy Rating, Announces Price Target of $13
JonesTrading Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $13
Editas Medicine Hold Rating With Revised Price Target Amidst Mixed Financial Signals
Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline
Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $7
Barclays Remains a Hold on Editas Medicine (EDIT)
Buy Rating on Editas Medicine as R&D Progress Signals Market Potential for Sickle Cell and Thalassemia Treatments
Editas Medicine Price Target Raised to $15.00/Share From $13.00 by B of A Securities
Buy Rating Reaffirmed for Editas Medicine Amidst Promising Clinical Advancements and Future Prospects
Editas Medicine Analyst Ratings
Truist Securities Adjusts Price Target on Editas Medicine to $12 From $20, Maintains Buy Rating
TD Cowen Sticks to Their Buy Rating for Editas Medicine (EDIT)
RBC Cuts Price Target on Editas Medicine to $8 From $11, Keeps Sector Perform, Speculative Risk
Editas Medicine Analyst Ratings
Oppenheimer Maintains Perform on Editas Medicine, Maintains $12 Price Target
Editas Medicine Analyst Ratings